# Hamlet BioPharma Proposes Dr. Joel Silver to Board, Adds Tara Heitner as Advisor

> Hamlet BioPharma will propose Dr. Joel Silver as a board member at its November 20, 2026 general assembly and brings on Dr. Tara Heitner.

- Published: 2026-11-20T09:41:38+00:00
- Section: Leadership
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-20/hamlet-biopharma-board-silver-heitner
- Source: [news.cision.com](https://news.cision.com/hamlet-biopharma-ab--publ-/r/hamlet-biopharma-strengthens-its-board-and-business-development-expertise,c4427278)

## Key takeaways

- Dr. Joel Silver will be proposed as a new board member at Hamlet BioPharma's annual general assembly on November 20, 2026.
- Dr. Tara Heitner joins Hamlet BioPharma as a business development advisor with licensing and commercialisation experience.
- Professor Bill Hansson leaves the Hamlet BioPharma board after five years and will continue working on drug development projects in Linnane Pharma.

Hamlet BioPharma will propose Dr. Joel Silver as a new board member at its annual general assembly on November 20, 2026, and has welcomed Dr. Tara Heitner as a business development advisor, [news.cision.com](https://news.cision.com/hamlet-biopharma-ab--publ-/r/hamlet-biopharma-strengthens-its-board-and-business-development-expertise,c4427278) reported. The company said the appointments add medical and commercial expertise as it runs a Phase III study of Alpha1H in bladder cancer.

## Silver's Record and Heitner's Licensing Role

Dr. Silver has more than 50 years of experience in healthcare and pharmaceuticals. His previous positions include Associate Medical Director at Pfizer Laboratories, Director of the Medical Department at Revlon Health Care and Regional Medical Director at Oxford Research International Corporation, and he is currently President of Silver and Company, advising on pharmaceutical development projects. His work includes a pioneering role in the introduction of BCG to the US market and a longstanding involvement in bladder cancer, including clinical trials and interactions with the FDA.

Dr. Heitner brings experience in drug development, licensing and commercialisation, and has led and signed pharmaceutical licensing agreements covering assets from early discovery to clinical development. As Head of Global Business Development at Ferring, she led late-stage business development and alliance management, work that included FDA interactions, preparation for product launches and evaluation of new opportunities. At Merck KGaA, she worked in scouting, evaluation and alliance management, mainly in oncology and immunology, and she holds a PhD in chemistry from McGill University and an Executive MBA from the Technical University of Denmark.

"It means a great deal to us that Joel Silver and Tara Heitner have chosen to work with Hamlet BioPharma," said Professor Catharina Svanborg, Chairman of the Board. "With our Phase III study under way, we are also continuing discussions on the further development and commercialisation of Alpha1H and additional substances in our portfolio."

## Alpha1H's Path to Phase III

Hamlet BioPharma announced the start of the clinical phase of its Phase III trial for non-muscle invasive bladder cancer, with patients enrolled at Motol hospital in Prague, news.cision.com reported in September 2026. In June 2026, Dagens industri reported that Hamlet Biopharma, listed on Spotlight, had received regulatory approval in Europe to conduct a Phase 3 study of Alpha1H for non-muscle invasive bladder cancer. In October 2026, TradingView reported that Alpha1H had entered Phase III for non-muscle invasive bladder cancer, with early studies showing tumor reduction and a cell-shedding mechanism.

## Board Changes Across Oncology Peers

[858 Therapeutics](https://www.financialcontent.com/article/bizwire-2026-11-16-858-therapeutics-appoints-dr-srini-ramanathan-as-chief-executive-officer-to-lead-next-phase-of-company-growth) appointed Srini Ramanathan as CEO and Jeffrey Stafford as Executive Chairman on November 16, 2026, with Ramanathan to lead clinical development of its lead candidate ETX-19477, a PARG inhibitor for solid tumors. [Commit Biologics](https://www.globenewswire.com/news-release/2026/11/12/3401271/0/en/commit-biologics-nominates-first-development-candidate-from-bice-its-complement-system-engaging-platform-and-strengthens-senior-leadership.html) appointed Anne-Marie Levy Rasmussen as COO and Benjamin Ole Wolthers as Head of Clinical Development on November 12, 2026. [Juniper Biosciences](https://www.globenewswire.com/news-release/2026/11/11/3401165/0/en/juniper-biosciences-builds-clinical-and-commercial-leadership-teams-with-appointments-of-deepak-behera-m-d-as-chief-medical-officer-javed-mahmood-ph-d-as-senior-director-of-clinica.html) appointed Deepak Behera as Chief Medical Officer, Javed Mahmood as Senior Director of Clinical Development and Robert Sgroi as Chief Commercial Officer on November 11, 2026.

## Hansson's Departure From the Board

The Board thanked Professor Bill Hansson for his contributions during his five years on the Board of Hamlet BioPharma. Professor Hansson will continue working with the drug development projects from a more scientific angle, in Linnane Pharma.

## Companies in this story

- Hamlet BioPharma · website: http://hamletpharma.com

---
News for Agent · https://newsforagent.com/llms.txt
